A. A. Tahrani, S. Rangan and P. Moulik, “Grave’s Eye Disease Developing Following Radioiodine Treatment for Toxic Nodular Goiter,” Experimental and Clinical Endocrinology & Diabetes, Vol. 115, No. 7, 2007, pp. 471-473. - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

A. A. Tahrani, S. Rangan and P. Moulik, “Grave’s Eye Disease Developing Following Radioiodine Treatment for Toxic Nodular Goiter,” Experimental and Clinical Endocrinology & Diabetes, Vol. 115, No. 7, 2007, pp. 471-473.
http://dx.doi.org/10.1055/s-2007-970400

has been cited by the following article:

TITLE: Grave’s Eye Ophthalmopathy Developing Following Radioiodine Therapy for Toxic Adenoma

AUTHORS: Hala Chafic Ahmadieh, Ibrahim Salti

KEYWORDS: Grave’s Ophthalmopathy; Toxic Adenoma; Toxic Nodular Goiter; Radioiodine Therapy

JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.3 No.6, October 24, 2013

ABSTRACT: The development of Grave’s ophthalmopathy following radioiodine treatment for Grave’s disease is well recognized. However, development of Grave’s ophthalmopathy following radioiodine therapy given for toxic adenoma or toxic nodular goiter has been reported but very rarely. Hereby, we reported a case of a 69-year-old male patient who developed ophthalmopathy after receiving 30 mCi (1110 mBq) 131 I radioiodine treatment for a toxic nodule. In addition, a review of the current literature with regards to this topic is presented.